KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) EBT Margin (2016 - 2025)

Nektar Therapeutics has reported EBT Margin over the past 16 years, most recently at 159.13% for Q4 2025.

  • Quarterly results put EBT Margin at 159.13% for Q4 2025, down 18313.0% from a year ago — trailing twelve months through Dec 2025 was 281.52% (down 16041.0% YoY), and the annual figure for FY2025 was 281.52%, down 16041.0%.
  • EBT Margin for Q4 2025 was 159.13% at Nektar Therapeutics, up from 297.04% in the prior quarter.
  • Over the last five years, EBT Margin for NKTR hit a ceiling of 975.05% in Q4 2023 and a floor of 736.47% in Q2 2022.
  • Median EBT Margin over the past 5 years was 276.89% (2022), compared with a mean of 277.5%.
  • Biggest five-year swings in EBT Margin: surged 123180bps in 2023 and later tumbled -95105bps in 2024.
  • Nektar Therapeutics' EBT Margin stood at 587.02% in 2021, then surged by 56bps to 256.75% in 2022, then surged by 480bps to 975.05% in 2023, then plummeted by -98bps to 24.0% in 2024, then plummeted by -763bps to 159.13% in 2025.
  • The last three reported values for EBT Margin were 159.13% (Q4 2025), 297.04% (Q3 2025), and 352.53% (Q2 2025) per Business Quant data.